We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Although the data in the current trial support expanding consideration of left atrial appendage closure for selected patients on a case-by-case basis, they are likely to be insufficient for a definitive declaration that this approach is as efficacious as conventional NOAC therapy in the great majority of patients with atrial fibrillation.”
“The CLOSURE-AF study raises the burden of proof to demonstrate at worst equivalence, if not superiority, of the device, and I don't think that CHAMPION-AF convincingly provided that proof.”
“Our data suggest that the LAA closure device used in this trial is a potential and reasonable alternative to medication, even among patients who are suitable for long-term blood thinners, and may be discussed as part of a shared decision-making process.”
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Gregory M. Marcus (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: